Choa Pharmaceutical narrows loss in Q1 2026, but remains undercapitalized with high debt
-
Consolidated revenue of KRW 14.68 billion (vs. KRW 14.37 billion in prior quarter), operating loss of KRW 1.12 billion (vs. KRW 2.11 billion), net loss of KRW 0.15 billion (vs. KRW 2.20 billion), showing significant narrowing of losses.
KOSDAQ Filing Information
- Filing: Quarterly Report (2026.03)
- Company: ChoA Pharmaceutical (034940)
- Submission: ChoA Pharmaceutical Co., LTD.
- Receipt: 05-15-2026